| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8528315 | Clinical Therapeutics | 2017 | 9 Pages |
Abstract
Adding ramucirumab to a regimen of paclitaxel in the second-line treatment of advanced gastric cancer is expected to provide a minimal incremental benefit at a high incremental cost per QALY. Based on our findings, adjustments in the price of ramucirumab, as well as improves in other clinical parameters such as survival time and adverse event in advanced gastric cancer therapy, are needed.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Shota Saito, Yusuke Muneoka, Takashi Ishikawa, Kouhei Akazawa,